MicuRx presents promising antibiotic research results for NTM lung disease and Pseudomonas aeruginosa at the 7th World Bronchiectasis Conference.
MicuRx presented innovative antibiotic research results for MRX-5 and MRX-8 at the 7th World Bronchiectasis Conference. Their research supports the potential of these pipeline products in treating Nontuberculous Mycobacteria (NTM) lung disease and Pseudomonas aeruginosa infections, providing hope for future treatments. The conference, held in Dundee, Scotland, focused on bronchiectasis research and treatment.
July 18, 2024
4 Articles